Clinical Trial: Efficacy of Adding Topiramate to Current Treatment in Refractory Obsessive Compulsive Disorder (OCD)

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: A Study of Topiramate Augmentation in Serotonin Reuptake Inhibitor (SRI) -Refractory Obsessive Compulsive Disorder

Brief Summary: SRI's are considered first-line treatments for OCD, however many patients continue to have significant symptoms despite an adequate trial of an SRI. Neuroimaging studies have shown that the glutamate neurological system is involved in OCD. This study will test the safety and efficacy of topiramate, a drug, which targets glutamate, in the treatment of OCD, where the OCD has been un-responsive, or partially responsive to regular SRI treatment.

Detailed Summary:
Sponsor: Hamilton Health Sciences Corporation

Current Primary Outcome:

  • Yale-Brown Obsessive Compulsive Scale (Y-BOCS) [ Time Frame: 12 weeks ]
  • Clinical Global Impression - Improvement ≤ 2 [ Time Frame: 12 weeks ]


Original Primary Outcome:

  • Yale-Brown Obsessive Compulsive Scale (Y-BOCS)
  • Clinical Global Impression - Improvement ≤ 2


Current Secondary Outcome:

  • Montgomery Asberg Depression Rating Scale [ Time Frame: 12 weeks ]
  • Sheehan Disability Scale [ Time Frame: 12 weeks ]
  • Beck Depression Inventory [ Time Frame: 12 weeks ]
  • PI-SWUR Hoarding Scale [ Time Frame: 12 weeks ]
  • Self Report Y-BOCS [ Time Frame: 12 weeks ]


Original Secondary Outcome:

  • Montgomery Asberg Depression Rating Scale
  • Sheehan Disability Scale
  • Beck Depression Inventory
  • PI-SWUR Hoarding Scale
  • Self Report Y-BOCS


Information By: McMaster University

Dates:
Date Received: September 14, 2005
Date Started: January 2002
Date Completion: April 2019
Last Updated: March 21, 2017
Last Verified: March 2017